Name
Cartesian Therapeutics
What We Do
Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The
Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis
and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune
indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T
currently being evaluated in a Phase 1 trial in patients with multiple myeloma
Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis
and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune
indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA CAR-T
currently being evaluated in a Phase 1 trial in patients with multiple myeloma
Address
7495 New Horizon Way
Frederick, MD 21703
United States
Frederick, MD 21703
United States